Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Scoring treatment response in patients with relapsing multiple sclerosis.

Sormani MP, Rio J, Tintorè M, Signori A, Li D, Cornelisse P, Stubinski B, Stromillo Ml, Montalban X, De Stefano N.

Mult Scler. 2013 Apr;19(5):605-12. doi: 10.1177/1352458512460605. Epub 2012 Sep 25.

PMID:
23012253
2.
3.
4.
5.

Management of worsening multiple sclerosis with mitoxantrone: a review.

Fox EJ.

Clin Ther. 2006 Apr;28(4):461-74. Review.

PMID:
16750460
6.

Natalizumab for relapsing remitting multiple sclerosis.

Pucci E, Giuliani G, Solari A, Simi S, Minozzi S, Di Pietrantonj C, Galea I.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007621. doi: 10.1002/14651858.CD007621.pub2. Review.

PMID:
21975773
7.

PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.

Cohen BA, Rivera VM.

Curr Med Res Opin. 2010 Apr;26(4):827-38. doi: 10.1185/03007991003604018. Review. Erratum in: Curr Med Res Opin. 2010 Aug;26(8):1826. Dosage error in article text.

PMID:
20121658
8.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
9.

The challenges of measuring disability accumulation in relapsing-remitting multiple sclerosis: evidence from interferon beta treatments.

Kieseier BC.

Expert Rev Neurother. 2014 Jan;14(1):105-20. doi: 10.1586/14737175.2014.869478. Review.

PMID:
24417500
10.

MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials.

Sormani MP, Bruzzi P.

Lancet Neurol. 2013 Jul;12(7):669-76. doi: 10.1016/S1474-4422(13)70103-0. Epub 2013 Jun 3. Review.

PMID:
23743084
11.

Management of relapsing-remitting multiple sclerosis in Latin America: practical recommendations for treatment optimization.

Correale J, Abad P, Alvarenga R, Alves-Leon S, Armas E, Barahona J, Buzó R, Corona T, Cristiano E, Gracia F, Bonitto JG, Macías MA, Soto A, Vizcarra D, Freedman MS.

J Neurol Sci. 2014 Apr 15;339(1-2):196-206. doi: 10.1016/j.jns.2014.02.017. Epub 2014 Feb 22. Review.

PMID:
24607335
12.

Predicting responders to therapies for multiple sclerosis.

Río J, Comabella M, Montalban X.

Nat Rev Neurol. 2009 Oct;5(10):553-60. doi: 10.1038/nrneurol.2009.139. Review.

PMID:
19794514
13.

Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis.

Río J, Ruiz-Peña JL.

J Neurol Sci. 2016 Feb 15;361:158-67. doi: 10.1016/j.jns.2015.12.043. Epub 2015 Dec 29. Review.

PMID:
26810535
14.

[Treatment of relapses of multiple sclerosis (a review)].

Brkovich RR, Totolian NA, Sokolov AIu, Ignatov IuD, Skoromets AA.

Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(10 Pt 2):69-77. Review. Russian.

PMID:
24416811
15.

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis.

Rudick RA, Polman CH.

Lancet Neurol. 2009 Jun;8(6):545-59. doi: 10.1016/S1474-4422(09)70082-1. Review.

PMID:
19446274
16.

MR Imaging in Monitoring and Predicting Treatment Response in Multiple Sclerosis.

Río J, Auger C, Rovira À.

Neuroimaging Clin N Am. 2017 May;27(2):277-287. doi: 10.1016/j.nic.2017.01.001. Epub 2017 Feb 14. Review.

PMID:
28391786

Supplemental Content

Support Center